Acquired Platinum Resistance of BRCA1-associated Ovarian Cancer after Neoadjuvant Chemotherapy
T. V. Gorodnova,
A. P. Sokolenko,
Kh. B. Kotiv,
A. O. Ivantsov,
E. A. Nekrasova,
Z. N. Ibragimov,
I. V. Berlev,
E. N. Imyanitov https://doi.org/10.31550/1727-2378-2022-21-5-87-91
Abstract
Objective of the Paper: To individualise the treatment programme for patients with advanced BRCA-associated ovarian cancer.
Key points. Ovarian cancer is a highly aggressive disease characterized by low overall survival rates. The search for molecular markers, predictors of the effectiveness of drug therapy, is an urgent area of research. The article describes a clinical case of a fundamentally new approach to the combined treatment of a patient with BRCA1-associated advanced ovarian cancer.
Conclusion. Molecular testing proved tumor resistance, which evolved during neoadjuvant therapy, so adjustment of the drug regimen was required. A comprehensive approach in the assessment of molecular genetic status and tumor prevalence allows to individualize the treatment program for patients with advanced BRCA-associated ovarian cancer.
Supporting agencies: Funding this work was supported grant RSF № 21-75-30015.
About the Authors
T. V. Gorodnova
N.N. Petrov National Medicine Research Center of Oncology
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
A. P. Sokolenko
N.N. Petrov National Medicine Research Center of Oncology; Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Minisrty of Healthcare of the Russian Federation
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
2 Litovskaya Str., Saint Petersburg, 194100
Kh. B. Kotiv
N.N. Petrov National Medicine Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov of the Minisrty of Healthcare of the Russian Federation
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
41 Kirochnaya Str., Saint Petersburg, 191015
A. O. Ivantsov
N.N. Petrov National Medicine Research Center of Oncology
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
E. A. Nekrasova
N.N. Petrov National Medicine Research Center of Oncology
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
Z. N. Ibragimov
LOKOD named after L.D. Roman
Russian Federation
Russian Federation
2 Zaozеrnaya Str., Kuzmolovsky, Saint Petersburg, 191014
I. V. Berlev
N.N. Petrov National Medicine Research Center of Oncology; North-Western State Medical University named after I.I. Mechnikov of the Minisrty of Healthcare of the Russian Federation
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
41 Kirochnaya Str., Saint Petersburg, 191015
E. N. Imyanitov
N.N. Petrov National Medicine Research Center of Oncology; Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State Pediatric Medical University” of the Minisrty of Healthcare of the Russian Federation
Russian Federation
Russian Federation
68 Leningradskaya Str., Pesochny, Saint Petersburg, 197758
2 Litovskaya Str., Saint Petersburg, 194100
References
1. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial ovarian cancer. Lancet. 2019; 393(10177): 1240–53. DOI: 10.1016/S0140-6736(18)32552-2
2. Kim N.Y., Jung D.C., Lee J.Y., Han K.H. et al. CT-based Fagotti scoring system for non-invasive prediction of cytoreduction surgery outcome in patients with advanced ovarian cancer. Korean J. Radiol. 2021; 22(9): 1481–9. DOI: 10.3348/kjr.2020.1477
3. Sokolenko A.P., Bizin I.V., Preobrazhenskaya E.V., Gorodnova T.V. et al. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: analysis of primary, residual and relapsed tumors. Int. J. Cancer. 2020; 146(7): 1879–88. DOI: 10.1002/ijc.32776
4. Gorodnova T.V., Kotiv K.B., Ivantsov A.O., Mikheyeva O.N. et al. Efficacy of neoadjuvant therapy with Cisplatin plus Mitomycin C in BRCA1-mutated ovarian cancer. Int. J. Gynecol. Cancer. 2018; 28(8): 1498–506. DOI: 10.1097/IGC.0000000000001352
5. Imyanitov E., Sokolenko A., Gorodnova T., Savonevich E. et al. Primary ovarian carcinomas arising in BRCA1 mutation carriers contain a small fraction of BRCA1-proficient cells with rapidly repopulate tumor mass during neoadjuvant chemotherapy but become outgrown by BRCA1-deficient clones during platinum — free intervals. Ann. Oncol. 2019; 30(S5): 763. DOI: https://doi.org/10.1093/annonc/mdz268.006
Review
For citations:
Gorodnova T.V., Sokolenko A.P., Kotiv Kh.B., Ivantsov A.O., Nekrasova E.A., Ibragimov Z.N., Berlev I.V., Imyanitov E.N. Acquired Platinum Resistance of BRCA1-associated Ovarian Cancer after Neoadjuvant Chemotherapy. Title. 2022;21(5):87-91. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-5-87-91
Views:
9
Email this article 